Understanding Lyme disease.

Lyme disease is a bacterial infection caused primarily by Borrelia burgdorferi, transmitted to humans through the bite of infected blacklegged ticks (Ixodes scapularis in the eastern US, Ixodes pacificus in the west). The bacteria can also be carried by other tick species and, in some cases, other biting insects, though tick transmission is the most documented route.

The name comes from Old Lyme, Connecticut, where an unusual cluster of arthritis cases in children was investigated in the mid-1970s. Researcher Willy Burgdorfer identified the causative bacteria in 1982. The disease had likely existed long before it was named.

For many patients, Lyme resolves with a standard course of antibiotics, particularly when caught early. For others, symptoms persist or evolve over months and years -- a reality that remains underacknowledged by many mainstream institutions and actively debated in the medical literature.

Transmission requires an infected tick to attach and feed for a sustained period -- generally estimated at 36 to 48 hours for Borrelia burgdorferi. However, this window is not absolute. Other co-infecting organisms can transmit faster. Not every tick bite results in infection, and not every infected tick is carrying Lyme.

The classic sign of early Lyme is a distinctive expanding rash called erythema migrans, often described as a bull's-eye pattern. However, the rash does not appear in every case -- some estimates suggest it is absent in 20 to 30 percent of infections. The absence of a rash does not rule out Lyme disease.

Ticks are most active in spring and fall but can be found year-round in temperate climates. They do not jump or fly -- they climb vegetation and attach to passing hosts. They are often the size of a poppy seed in the nymph stage, which is when most human infections occur.

The standard CDC-endorsed approach to testing Lyme disease is a two-tier system: an initial ELISA (enzyme-linked immunosorbent assay) followed by a Western blot if the ELISA is positive or equivocal. This system has real limitations. It is calibrated to detect antibody responses, which can be absent or low in early infection or in patients who received early antibiotic treatment.

The result is a clinical reality many patients know intimately: a negative test does not mean you do not have Lyme disease. Seronegative Lyme -- infection without a positive antibody response -- is documented in the medical literature and is a significant reason why patients cycle through years of wrong diagnoses.

Alternative labs like IGeneX use different band inclusion criteria and may detect responses the standard two-tier test misses. The medical community is divided on how to interpret these results. The debate between the CDC/IDSA framework and the ILADS (International Lyme and Associated Diseases Society) framework reflects genuine scientific disagreement, not fringe opinion. Our research library covers these controversies in detail.

The same ticks that carry Borrelia often carry other pathogens. The most common co-infections seen in Lyme patients include Babesia (a malaria-like parasite), Bartonella (a bacterial infection associated with psychiatric symptoms, stretch marks, and neurological effects), Anaplasma, Ehrlichia, and Mycoplasma.

Co-infections complicate the clinical picture significantly. A patient who tests positive for Lyme but does not improve on standard antibiotic treatment may have an untreated co-infection. Babesia requires different treatment than Borrelia. Bartonella requires different treatment again. A clinician who does not test for co-infections may treat the Lyme and miss what is actually driving the symptoms.

This is one of the core arguments in the ILADS framework: that a single-pathogen approach to diagnosis and treatment fails patients who are carrying multiple organisms. The Foundation documents these arguments as education. We do not make treatment recommendations.

Post-treatment Lyme disease syndrome (PTLDS), chronic Lyme, and persistent Lyme are terms used to describe a condition where symptoms continue or recur after standard antibiotic treatment. The mainstream medical position, reflected in CDC guidance, is that persistent symptoms are generally not caused by ongoing active infection. The ILADS position is that persistent infection is possible and that extended or combination antibiotic therapy may be appropriate in some cases.

This disagreement is real, unresolved, and has consequences for patients every day. People with persistent symptoms are frequently told their Lyme is cured, that their ongoing suffering is functional, psychological, or simply not Lyme. Some of these patients are right to push back. Some of the dismissal is institutional inertia rather than settled science.

The Foundation documents both sides of this debate because patients deserve to understand the landscape they are navigating. We are not here to tell you what to do about it. We are here to help you understand what the conversation actually looks like.